BioSpace News Archive

Vantage Galan with Advanced intelligent Clear-IQ Engine Provides High-Quality Images and Fast Exam Times

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Galmed Pharmaceuticals Ltd. announces that they have entered into a research agreement aiming at combination therapy of ASC41 and Aramchol for the treatment of non-alcoholic steatohepatitis.

Preclinical study at Emory University explores relationship between cellular NAD+ and retinal damage

Ra Medical Systems, Inc., a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 1:00 p.m. Eastern time.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States.

In PNEU-AGE (V114-019), V114 Demonstrated Non-inferiority to the Currently Available 13-valent Pneumococcal Conjugate Vaccine for Shared Serotypes and Met Study-Defined Superiority Criteria for Unique Serotypes 22F and 33F and Shared Serotype 3

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that the company will present at two investor conferences in September.

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the following virtual investor conferences in September

Kaleido Biosciences, Inc., announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferences in September.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the H.C. Wainwright 22nd Annual Global Investment Conference.